UPL Limited
5,909words
1turns
0analyst exchanges
1executives
Management on call
Examples Of Forward
looking
Key numbers — 40 extracted
8%
50%
47%
3%
2%
38%
14%
30%
rs
12,000
53%
33%
rs
33
Guidance — 5 items
Notes
opening
“2 Considers the highest expected sales by project in any given year, risk adjusted per internal estimates assigning technical probability of success to the best of our knowledge at the time of the projection; does not consider commercial risks 3 New molecules defined as new Active Ingredients and BioSolutions Capital Markets Day 2025 31 Resilient Core.”
Notes
opening
“Q4FY24) 6 18 6 20 Q4FY25 45 41 Q4FY24 32 33 Asia / AME Americas Australia Europe Capital Markets Day 2025 40 Public Advanta FY25 Healthy all-round operational performance Particulars (₹ in billions) Revenue Contribution Margin (%) Fixed Overheads EBITDA FY25 46.3 57.8% 14.9 11.8 FY24 Change (%) 41.5 57.1% 13.0 10.7 12% 70bps 15% 11% EBITDA Margin (%) 25.5% 25.7% (20bps) Regional Mix (FY25 vs.”
Notes
opening
“FY24) 2 11 2 11 FY25 52 FY24 49 35 38 Asia / AME Americas Australia Europe Revenue +12% vs.”
Notes
opening
“LY • Continued strong performance in FY25 (record sales and collections vs.”
Notes
opening
“The carved accounts of Superform are audited only for FY 2023-24 & FY 2024-25 Capital Markets Day 2025 52 Public UPL Group FY26 Outlook Anand Vora, Chief Financial Officer Public UPL Ltd.”
Risks & concerns — 2 flagged
2 Considers the highest expected sales by project in any given year, risk adjusted per internal estimates assigning technical probability of success to the best of our knowledge at the time of the projection; does not consider commercial risks 3 New molecules defined as new Active Ingredients and BioSolutions Capital Markets Day 2025 31 Resilient Core.
— Notes
India Emerging as Alternate Supply Location De-risk Supply Chains.
— Notes
Speaking time
1
Opening remarks
Notes
1 Innovation sales is defined as sales from products launched in the last 5 years. Innovation rate is innovation sales rate compared to total annual sales. 2 Considers the highest expected sales by project in any given year, risk adjusted per internal estimates assigning technical probability of success to the best of our knowledge at the time of the projection; does not consider commercial risks 3 New molecules defined as new Active Ingredients and BioSolutions Capital Markets Day 2025 31 Resilient Core. Future Ready. UPL SAS Ashish Dobhal, Chief Executive Officer 32 Public UPL SAS in FY25 FY25 key highlights | Transformed to drive sustainable growth Operational Excellence and Working Capital Efficiency Market & Channel Optimization Strategic Portfolio 1 • Prudent credit policies and working capital usage 2 • Placement aligned closely with season, dynamic forecasting 3 • Reduced SG&A and increased trainings 1 • Expanded beyond traditional focus: corn, sugarcane, rice 2 • Strengthened